drugset / Trial / NCT00737438
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Phase 2
Completed
22 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments. We also will find out the effects, both good and/or bad, a drug called bevacizumab has on you and your tumor when given with chemotherapy.
Timeline
- Start
- 2008-08
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |
| Subject | Epirubicin | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |